NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for F...(6 7380 6474 Distribution ...),Health

Date:11/5/2009

6 7,380 6,474 Distribution 3,267 3,472 10,476 10,202 General and administrative 4,808 4,744 14,512 14,443 ----- ----- ------ ------ Total operating expenses 18,231 17,041 54,459 52,056 ------ ------ ------ ------ Loss from operations (8,686) (12,259) (29,042) (38,841) ------ ------- ------- ------- Other expense: Interest income 7 146 32 453 Interest expense (1,130) (1,017) (5,502) (2,908) Change in fair value of financial instruments - (1,835) - 251 Other (expense) income, net (59) 138 20 (155) --- --- -- ---- (1,182) (2,568) (5,450) (2,359) ------ ------ ------ ------ Net loss before income taxes (9,868) (14,827) (34,492) (41,200) Provision for income taxes 179 143 298 248 -------- -------- -------- -------- Net loss $(10,047) $(14,970) $(34,790) $(41,448) ======== ======== ======== ======== Net loss per share, basic and diluted $(0.22) $(0.33) $(0.75) $(1.03) ====== ====== ====== ====== Weighted-average shares outstanding, basic and diluted 46,672 45,067 46,600 40,204 ====== ====== ====== ====== NxStage Medical, Inc. Condensed Consolidated Balance Sheets (in thousand
'/>"/>

SOURCE NxStage Medical, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Report Third Quarter 2009 Financial Results
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress